BioSpace News Archive

ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced that Adrian Woolfson, BM BCh, PhD, has joined its Board of Directors and Scientific Advisory Board to help guide the company’s strategy as it expands into drug discovery.

EV Biologics Corp, OTC PINK:YECO announced that it has signed an agreement with Lonza Cell Bio Services to implement a custom cell isolation in preparation for a novel, clonal, master cell bank.

atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc.

Eurofins Abraxis, announces that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of Glyphosate, Eurofins Abraxis Glyphosate ELISA Kit, has been granted AOAC Research Institute Performance Tested Methods (PTM) status (AOAC Cert. No. 072104) for use with whole grain durum wheat, whole grain oats, oat groats, dried yellow peas, and dried red lentils.

The global surgical suture market accounted to US$ 2,954.5 Mn in 2017 and is expected to grow at a CAGR of 5.4% during the forecast period 2018 - 2025, to account to US$ 4,503.3 Mn by 2025.

CJB Applied Technologies announced the opening of its new Bioconversions Lab, a resource highlighting the company’s resolve to invest in assets and capabilities that benefit its customers.

Dr. Greenshaw is a Fellow of the Royal Society of Arts; a Fellow of the Canadian College of Neuropsychopharmacology (CCNP), for which he served as President from 2000-2002; and a fellow of the Collegium Internationale Neuropsychopharmacologicum (CINP).

Oncologists and pathologists in the United States can now access a new in vitro diagnostic (IVD) test that screens for Lynch syndrome in patients with colorectal cancer.

Castor, a leading provider of clinical trial technology to democratize clinical research, today announced a full patient onboarding experience to enhance patient enrollment, from recruitment to first study visit.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2021 second quarter financial results on Tuesday, August 17, 2021, at 8:30 am ET before the U.S. financial markets open.